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bwu2000@yahoo.cAbstract The present study aimed to prepare a chemically and physically stable formulation of
doxycycline (Doxy) in an in situ thermally sensitive hydrogel for ophthalmic delivery. An inclusion
complex of Doxy and hydroxypropyl-b-cyclodextrin (HP-b-CD) was ﬁrst developed to increase the
stability of Doxy in aqueous solution. The physical characteristics (phase solubility proﬁles, thermal
analysis, X-ray powder diffractograms and infrared spectra) of the Doxy-HP-b-CD inclusion complex
indicated the formation of a stable 1:1 complex. Poloxamers P407 (16–22%) and P188 (0–5%) were
mixed to obtain a hydrogel with an appropriate gelation temperature for opthalmic use. Formulation of
the inclusion complex in the poloxamer hydrogel exhibited a suitable gelation temperature (33.3 1C) after
dilution with simulated tear ﬂuid (Gel:STF¼40:7, v/v). The release of Doxy from the poloxamer hydrogel
followed a zero order equation suggesting it occurs through corrosion of the poloxamer hydrogel.
Stability studies demonstrated that the inclusion of Doxy by HP-b-CD markedly improved its stability in
aqueous solution both at 8 and 40 1C. This formulation of a doxycycline-HP-b-CD inclusion complex in
an in situ thermally sensitive poloxamer hydrogel represents a potentially effective ophthalmic Doxy
delivery system.
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Doxycycline and hydroxypropyl-b-cyclodextrin complex in poloxamer thermal sensitive hydrogel 2551. Introduction
Corneal neovascularization (CNV) is a common complication
of many inﬂammatory, infectious and degenerative ocular
diseases and traumatic disorders resulting from chemical and
thermal injuries and irritation due to contact lens wear1. CNV
is one of the main sight-threatening conditions and has been
reported in 4.14% of patients presenting for general ophthal-
mologic care in the USA2. Clearly, CNV constitutes a great
economic and psychological burden for individuals, families
and society.
CNV involves degradation and remodeling of the underlying
basement membrane followed by proliferation of the surround-
ing extracellular matrix (ECM) and migration of vascular
endothelial cells into the tissue. Matrix metalloproteases (MMPs)
play an important role in degradation of basement membranes
and ECM proliferation and research has shown that increased
expression of MMP-2 and MMP-9 occurs in CNV3.
Tetracyclines are broad spectrum antibiotics used systemi-
cally and locally in the treatment of several infectious diseases
because they exert biological effects independent of their
antimicrobial activity4. In fact, tetracyclines inhibit MMPs
and prevent pathogenic tissue destruction in cases of CNV. As
a member of the tetracycline family, doxycycline (Doxy)
inhibits MMPs by a number of mechanisms including tran-
scriptional inhibition5, direct effects on the post-translational
level by coordination with the catalytic site4, and indirect
effects by inﬂuencing endogenous inhibitors or activators6.
Much research7–9 has shown that Doxy can effectively inhibit
CNV on topical administration but this application is limited
by its relatively low stability in aqueous solution.
Cyclodextrins (CDs), commonly used to form inclusion
compounds with hydrophobic molecules, show great advan-
tages in enhancing the stability of guest molecules. Hydro-
xypropyl-b-cyclodextrin (HP-b-CD) is a particularly useful
CD because of its high solubility in aqueous solution and the
fact that it is non-irritant to skin, eyes and mucosa10. This has
led to its frequent application in ophthalmic preparations. In
addition, divalent metal ions (Mg2þ, Mn2þ, Co2þ, Ni2þ, Cu2þ,
Zn2þ and Cd2þ) can chelate Doxy to increase its stability11,12.
Traditional liquid formulations for ophthalmic use have
limited efﬁcacy because their residence time in the eye is
limited by lacrimal secretion and nasolacrimal drainage13. As
a result, the absorption of topically administered ocular drugs
is only 1–10%14. In order to improve ocular bioavailability,
polymers have been used to form hydrogels to increase
solution viscosity. Moreover, to improve the accuracy and
reproducibility of hydrogel administration, in-situ forming
hydrogels have been developed, which are in the liquid state
before administration and undergo a phase transition to form
a transparent gel when their environment is changed15. Such
environmental changes can involve changes in temperature,
pH or electrolyte composition16.
In a previous study, Kim et al.17 successfully prepared an
in-situ hydrogel forming system containing a CD complex of
rhEGF to enhance its stability and therapeutic efﬁcacy for
ophthalmic use. Based on this formulation, we investigated an
in situ hydrogel forming formulation containing a Doxy
inclusion complex to treat CNV. This paper reports the
development and characterization of the inclusion complex
and hydrogel and the results of a pharmacodynamic study of
the hydrogel formulation in animals.2. Materials and methods
2.1. Materials
Doxy monohydrate (purity 98.5%) and Doxy hydrochloride
(purity 92.5%) were kindly provided by Yancheng Suhai
Pharmaceutical Co. (Jiangsu, China). Hydroxypropyl-b-cyclo-
dextrin (HP-b-CD) was provided by Roquette (Lestrem,
France). Poloxamer 407 and 188 were provided by BASF
Co. (Ludwigshafen, Germany). All other reagents were of
analytical grade.
2.2. Doxy-HP-b-CD complex
2.2.1. Phase solubility studies
Phase solubility studies were carried out in distilled water
according to the method described by Higuchi and Connors18.
Excess Doxy monohydrate (10 mg) was added to 2 mL aliquots of
aqueous solutions and magnesium chloride solutions (0.5 wt%)
containing various concentrations of HP-b-CD (0–130 mg/mL).
The suspensions were then stirred at 2572 1C for 24 h, ﬁltered
through 0.45 mm membrane ﬁlters and appropriately diluted. The
concentration of Doxy was determined by HPLC. Experiments
were performed in triplicate.
2.2.2. Preparation and characterization
A Doxy-HP-b-CD solution was prepared by adding Doxy
monohydrate to a solution containing magnesium chloride
(0.5 wt%) and HP-b-CD to give a ﬁnal Doxy:HP-b-CD molar
ratio in the range 1:4–1:6. The solution was stirred at 2572 1C
for 24 h during which all solid material dissolved. The solution
was then ﬁltered through a 0.45 mm membrane ﬁlter and either
used immediately or concentrated by rotary evaporation and
dried under vacuum for later characterization.
2.2.3. Thermal analysis
Thermogravimetric analysis/simultaneous differential thermal
analysis (SDA/SDTA) of the Doxy-HP-b-CD complex was
performed using a TGA/SDTA 851e instrument (Mettler-
Toledo, Switzerland) equipped with a thermal analysis data
analyzer. Samples were placed in a holed crucible and scanned
from 25 to 250 1C at a rate of 10 1C/min using nitrogen as
purging gas at a ﬂow rate of 40 mL/min. Thermograms of the
pure constituents, a physical mixture and the inclusion complex
were obtained.
2.2.4. X-ray powder diffraction
X-ray powder diffraction (XRPD) patterns were obtained
using an X-ray powder diffractometer (Rigaku Corporation,
Model D/Max-IIIA, Japan) with a diffracted beam mono-
chromator and a conventional copper target X-ray tube
set at 35 kV and 25 mA with Cu Ka radiation. The 2y scan
range was 3–601 with a step size of 0.0201 and the scan speed
of 2.51/min.
2.2.5. Infrared spectroscopy
Infrared spectra in the range 400–4000 cm1 were measured in
KBr disks containing the pure substances, physical mixture
and inclusion complex using an FT-IR spectrometer (Bruker,
TENSOR37, Germany).
Zi-xin He et al.2562.3. Preparation of poloxamer gel
The poloxamer gel was prepared by the cold method19 in
which poloxamers P407 and P188 were agitated uniformly in a
solution of the Doxy-HP-b-CD complex at room temperature.
The mixture was then placed in a refrigerator at 4 1C for 24 h
during which it swelled completely and changed into a ﬂuid
solution.2.4. Measurement of gelation temperature
The gelation temperatures of poloxamer gels produced using
different ratios of P407 and P188 and poloxamer gels containing
Doxy-HP-b-CD were measured by rheology20. Aliquots (approxi-
mately 8 mL) of each sample were added into the sample cell of a
Brookﬁeld DV-III Ultra programmable rheometer (Brookﬁeld
Engineering Labs Inc., USA) and the instrument operated at a
rotation speed appropriate to the torque and a temperature rising
at 0.5 1C/min. Viscosity was recorded every 0.5 1C and the
gelation temperature obtained from the viscosity proﬁle.2.5. In vitro release
Doxy release from the Doxy-HP-b-CD poloxamer gels was
determined in simulated tear ﬂuid (STF)21 (2.18 g sodium
bicarbonate, 6.78 g sodium chloride, 0.032 g anhydrous cal-
cium chloride and 1.38 g potassium chloride in 1 L of water; 290
mosm/L, pH 7.8). Approximately 3.0 g poloxamer solution was
poured into a weighing bottle (j 22 mm 50 mm) preheated to
33.5 1C to transform the solution into a gel. STF (1.5 mL) was
then poured gently down the wall of the bottle onto the top of the
gel and the vessel shaken horizontally at a constant rate in a water
bath at 33.5 1C. At various times, the solution was decanted off
and collected and the vessel wiped dry and weighed. An aliquot of
fresh STF was then added on top of the gel and the vessel again
shaken at 33.5 1C. The steps were repeated until the weight of the
remaining gel changed by no more than 10% of the initial weight
in that incubation period. All solutions were combined, immedi-
ately ﬁltered through a 0.45 mm membrane ﬁlter, suitably diluted
and analyzed for Doxy by HPLC. Each experiment was
performed in triplicate.2.6. Stability studies
Doxy and the Doxy-HP-b-CD hydrogel were stored at 40 1C for
10 days to evaluate stability at elevated temperature. Drug
content was determined initially and after 5 and 10 days by
HPLC. Other samples stored at 8 1C for 30 days to assess
stability in the cold were sampled initially and after 10, 20 and
30 days.Figure 1 Phase solubility of Doxycycline in HP-b-CD solution
(n¼3).2.7. Doxycycline
Samples were assayed by reversed phase HPLC with UV detection
at 280 nm. Separation was performed on a 250 mm 4.6 mm
Luna C18 (2) 5 mm column (Phenomenex, USA) maintained at
35 1C using a mobile phase containing 0.05 mol/L ammonium
oxalate, dimethylformamide and 0.2 mol/L dibasic ammonium
phosphate in the ratio 65:30:5 and pH 8.070.2.3. Results and discussion
3.1. Characterization of Doxy-HP-b-CD complex
3.1.1. Phase solubility studies
The phase solubility proﬁles of Doxy in aqueous solutions of
HP-b-CD are presented in Fig. 1. The linearity of the proﬁles
indicates that the aqueous solubility of Doxy monohydrate
increases linearly as the HP-b-CD concentration increases in
both water and 0.5 wt% MgCl2 solution. The phase solubility
proﬁle can be classiﬁed as AL-type according to Higuchi and
Connors18 suggesting the formation of a 1:1 complex between
Doxy and HP-b-CD molecules.
The apparent stability constant K (also called the binding
constant) can be calculated for a 1:1 complex according to the
following equation22:
K1:1 ¼ s=S0ð1sÞ ð1Þ
where S0 is the solubility of Doxy in the absence of HP-b-CD
and s is the slope of the linear plot of Doxy dissolved in HP-b-
CD solution. From Fig. 1, the values of S0 for Doxy were
0.0034 mol/L in water and 0.0077 mol/L in MgCl2 solution.
Corresponding values of s were 0.0291 and 0.1534, respectively.
This data give K1:1 values of 31.23 (mol/L)
1 in water and 120.80
(mol/L)1 in 0.5 wt% MgCl2 solution. These values show that
Doxy and HP-b-CD form a stable complex whose stability is
increased in the presence of Mg2þ.3.1.2. Thermal analysis
TGA/SDTA can be used to detect the presence of an inclusion
complex. When a guest molecule is embedded in CD cavity or
in the crystal lattice, its melting, boiling or sublimation point
generally shifts to a different temperature or disappears
entirely. The thermograms of Doxy and the binary systems
(Fig. 2) exhibit endothermic peaks at 148.0 and 176.0 1C. The
thermogram of HP-b-CD shows a smooth curve over the
range 50–300 1C with an endothermic peak at 358.0 1C. For
the physical mixture of Doxy and HP-b-CD, the Doxy
endothermic peaks can be clearly observed but, in the
thermogram of the inclusion complex, both endothermic
peaks of Doxy disappear and only the phase-transition peak
Figure 2 TGA/SDTA diagrams of Doxy-HP-b-CD systems. (A)
Doxy; (B) HP-b-CD; (C) Physical mixture of Doxy and HP-b-CD
in the molecular ratio of 1:4; (D) Inclusion complex of Doxy and
HP-b-CD in the molecular ratio of 1:4.
Figure 3 PXRD diagrams of Doxy-HP-b-CD systems. (A) Doxy;
(B) HP-b-CD; (C) Physical mixture of Doxy and HP-b-CD in
the molecular ratio of 1:4; (D) Inclusion complex of Doxy and
HP-b-CD in the molecular ratio of 1:4.
Figure 4 Infrared spectrograms of Doxy- HP-b-CD systems. (A)
Doxy; (B) HP-b-CD; (C) Physical mixture of Doxy and HP-b-CD
in the molecular ratio of 1:4; (D). Inclusion complex of Doxy and
HP-b-CD in the molecular ratio of 1:4.
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HP-b-CD form an inclusion complex by clathrate formation.
3.1.3. X-ray powder diffraction
As the environment of a guest molecule changes during
complexation, XRPD can also be used to explore the formation
of inclusion complexes. The XRPD diffractograms of Doxy and
the binary systems are shown in Fig. 3. Characteristic peaks (2y:
10.381, 15.421, 17.461, 19.141, 19.701, 22.321, 23.801) observed in
diffractogram of Doxy suggest it exists in a crystalline form. The
physical mixtures of Doxy and amorphous HP-b-CD also show
the presence of crystalline drug peaks. However, the inclusion
complex showed no characteristic peaks of Doxy consistent with
the formation of an inclusion complex.
3.1.4. Infrared spectroscopy
The infrared spectra are presented in Fig. 4. Doxy showed strong
C–H, N–H and O–H absorption bands between 3500 and
3000 cm1 and C¼O and C¼C stretches between 1700 and
1600 cm1. The HP-b-CD spectrum showed characteristic O–H,
CH and C–O–C bands at 3327, 2928 and 1030 cm1,respectively. Bands in the physical mixture were a combination
of those of Doxy and HP-b-CD while the infrared spectrum of the
inclusion complex was different supporting the formation of an
inclusion complex and suggesting the interaction is via the
–CONH2 group of Doxy.3.2. Effect of poloxamer composition on gelation temperature
The gelation temperature is the temperature at which a thermally
sensitive solution changes to a semisolid. The gelation temperature
of a gel for ophthalmic drug delivery should be around 33.5 1C
after dilution with STF (gel:STF ratio of 40:7, v/v)23. An ideal
in situ forming gel should be free ﬂowing at a low temperature,
transform into a semisolid after contacting the ocular surface, and
remain in the gel form under conditions of maximum lacrimal
ﬂuid dilution.
Poloxamers are commonly used materials for in situ gel
formation. They are ABA-type triblock copolymers composed
of polyethylene oxide (PEO) and polypropylene oxide (PPO)
units. As temperature increases, dehydration of PPO leads to
formation of a micelle core while hydration of PEO causes it
to expand and form an outer skin. As the temperature
continues to rise, the micelles arrange themselves in sequence
to form a hydrogel. Typically, the gelation temperature
depends on the PEO:PPO ratio in the polymer solution. In
the case of P407, it was found that a 16% solution trans-
formed into a hydrogel at 29.35 1C but, when diluted with
STF at a gel:STF ratio of 40:7 (v/v), phase transformation did
not happen even at temperatures up to 50 1C. Therefore P188
was included in the formulation to obtain an appropriate
gelation temperature for ophthalmic delivery. The results
show that with 16 wt%, 18 wt%, and 20 wt% P407 and
0–5 wt% w/w P188, the gelation temperature increased with
decreasing P407 concentration and increasing P188 concentra-
tion. This reﬂects the fact that with increasing concentrations
Figure 6 Effects of Doxy-HP-b-CD inclusion complexes concen-
tration on drug release. The poloxamer gel was composed of
21.15 wt% P407 and 3.53 wt% P188. The ratio of Doxy and HP-
b-CD was 1:4. Each point represents the mean7S.E. (n¼3).
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aggregation at a lower temperature leading the micelles to
become more entangled and closer resulting in an increase in
viscosity and greater ease of gelation. Concomitantly, the
addition of P188 increases the ratio of PEO leading the
micelles to become less entangled thereby raising the critical
micelle temperature (CMT)24.
According to the results in Table 1, a formulation containing
21.15 wt% P407 and 3.53 wt% P188 was chosen since it has a
gelation temperature of 33.5 1C when diluted with STF in a
gel:STF ratio of 40:7 (v/v). The gelation temperature of the gel
was also affected by the concentration of Doxy-HP-b-CD
complex as shown in Fig. 5. Here, increasing concentration of
Doxy-HP-b-CD from 0.1 wt% to 0.3 wt% causes a decrease in
gelation temperature from 24.83 to 24.00 1C and a greater
decrease from 33.33 to 31.00 1C after dilution with STF. This
phenomenon may be due to the salting-out effect of MgCl2 used
in the preparation of the inclusion complex25.
3.3. In vitro release studies
Figs. 6 and 7 show the in vitro release proﬁles of different
Doxy-HP-b-CD poloxamer gel formulations. Changing theTable 1 Effects of P407 and P188 concentration on the
gelation temperature of poloxamer.
Formulation Poloxamer
407 (wt%)
Poloxamer
188 (wt%)
Gelation
temperature
(1C)
1 16 0 29.1770.29
2 16 3 39.0070.50
3 16 5 41.3370.58
4 18 0 24.8370.76
5 18 3 31.5071.00
6 18 5 35.0070.50
7 20 0 22.3370.58
8 20 3 26.7370.40
9 20 5 29.4070.17
Figure 5 Effects of Doxy-HP-b-CD inclusion complex concen-
tration on gelatination temperature (each sample contains
21.15 wt% P407 and 3.53 wt% P188). (n¼3).
Figure 7 Effects of P407 and P188 concentration on drug release.
Each sample was composed of 0.2 wt% Doxy and the ratio of
Doxy and HP-b-CD was 1:4. Each point represents the
mean7S.E. (n¼3).initial Doxy-HP-b-CD concentration in the gel from 0.1% to
0.3 wt% did not affect the release proﬁles. But gels with lower
concentrations of P407 and higher concentrations of P188
produced faster release of Doxy.
In order to determine the release mechanism, the suitability of
two equations, the Higuchi model and zero-order model, were
tested with respect to the release data. These are described by the
following equations26,27:
Higuchi model : Mt ¼M0 þ KHt0:5 ð2Þ
Zero-order model : Mt ¼M0 þ K0t ð3Þ
where Mt is the amount of drug dissolved at time t, M0 is the
initial amount of drug in the sample and KH and K0 are the
Higuchi rate constant and zero-order release constant,
respectively.
The results of ﬁtting the release data to these models are
shown in Tables 2 and 3. Based on the correlation coefﬁcient
Doxycycline and hydroxypropyl-b-cyclodextrin complex in poloxamer thermal sensitive hydrogel 259(R2), release appears to ﬁt the zero order equation better than
the Higuchi equation suggesting release occurs by poloxamer
hydrogel corrosion. With increasing P407 concentration,
hydrogel corrosion is slower and drug release is decreased
whereas with increasing P188 concentration, hydrogelTable 2 Fitting of the kinetics models for Doxy-HP-b-
CD release from poloxamer gels with different Doxy
concentration.
Doxy (%) Higuchi equation Zero order equation
KH R
2 K0 R
2
0.1 50.9340 0.9517 16.318 0.9994
0.2 52.2418 0.9505 17.011 0.9947
0.3 51.9476 0.9479 16.575 0.9916
Table 3 Fitting of the kinetics models for Doxy-HP-b-CD relea
and P188.
Poloxamer Higuchi equation
P407 (%) P188 (%) KH
21.15 3.53 42.7386
21.15 0 20.3649
16.00 0 32.4210
Table 4 Stability of Doxy/HP-b-CD complex thermal sensitive h
Group Days Appearance
Doxy.HCl hydrogel (control) 0 Light yellow clear
5 Light brown minor depo
10 Brown more deposition
Doxy-HP-b-CD hydrogel 0 Light yellow clear
5 Light brown clear
10 Brown minor deposition
an¼3.
Table 5 Stability of Doxy/HP-b-CD complex thermal sensitive h
Group Days Appearance
Doxy.HCl hydrogel (control) 0 Light yellow clear
10 Light yellow clear
20 Light yellow clear
30 Light yellow clear
Doxy-HP-b-CD hydrogel 0 Light yellow clear
10 Light yellow clear
20 Light yellow clear
30 Light yellow clear
an¼3.hydrophilicity is increased allowing more water to enter and
drug release faster28.
3.4. Stability studies
Results of stability studies are summarized in Tables 4 and 5. In a
sample of Doxy hydrochloride poloxamer hydrogel containing
the same concentration of Doxy (0.1%) but no HP-b-CD, Doxy
degraded rapidly at 40 1C accompanied by a colour change from
yellow to brown and an increase in the concentration of related
substances of 16.471.0%. In contrast, in the Doxy-HP-b-CD
thermally sensitive hydrogel, the concentration of Doxy remained
at 90.671.0% after 10 day. In addition, the stability of the Doxy-
HP-b-CD thermally sensitive hydrogel was better than that of the
Doxy hydrochloride poloxamer hydrogel at 8 1C. These results
indicate that the addition of Mg2þ and the formation of an
inclusion complex enhance the stability of Doxy. This may be
because: (1) Mg2þ and Doxy form a chelate at the site of
the phenol diketone, which prevents Doxy from base and acidse from poloxamer gels with different concentrations of P407
Zero order equation
R2 K0 R
2
0.9425 17.096 0.9962
0.9170 8.2715 0.9993
0.8782 13.433 0.9959
ydrogels at 40 1C.
pH Contenta (%) Related substancea (%)
5.76 100.00 1.1270.45
sition 5.91 73.1579.60 7.4872.23
6.32 52.0372.27 16.4170.97
5.59 100.00 0.8470.41
5.59 95.9873.8 0.6670.15
5.56 90.6370.96 4.9470.15
ydrogels at 8 1C.
pH Contenta (%) Related substancea (%)
5.76 100.0070.00 1.1270.45
5.73 93.5273.07 1.5670.24
5.83 91.8872.51 2.5170.55
5.86 92.2770.75 2.3270.23
5.59 100.0070.00 0.8470.41
5.59 100.4974.87 0.6170.14
5.57 99.8575.30 1.1970.48
5.58 99.9874.90 1.0770.10
Zi-xin He et al.260catalyzed hydrolysis; and (2) HP-b-CD entraps Doxy in
an environment that protects the chemically labile groups
in Doxy.4. Conclusions
A formulation of a stable Doxy-HP-b-CD inclusion complex in
a thermally sensitive ophthalmic hydrogel has been prepared,
which remains as a free-ﬂowing liquid at room temperature and
changes into a hydrogel when exposed to temperatures above its
gelation point. The formation of a Doxy-HP-b-CD complex not
only enhanced the stability of Doxy, but also produced sustained
release of Doxy by a mechanism involving poloxamer corrosion.
Thus, an HP-b-CD inclusion complex is an effective way to
stabilize Doxy in aqueous solution and the poloxamer hydrogel
can be applied as an effective ophthalmic delivery system
for Doxy.
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